
Releases
Haisco Licenses Two Oncology and Complement Drugs to Nuvectis
Haisco Pharmaceutical Group has inked an exclusive global licensing deal with U.S.-based Nuvectis for two experimental drug candidates, HSK42360 and HSK39297. The agreement grants the American biotech development and commercialization rights outside of Greater China and specific Southeast Asian territories, aiming to fast-track these therapies for international patient populations.

























